ArticleJournal of thoracic disease2026
Impact of antimicrobial exposure on bronchoscopy yields in immunocompromised patients: a single-centre experience.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bronchoscopy with bronchoalveolar lavage (BAL) is an important diagnostic tool for pulmonary infections in immunocompromised hosts (ICH). However, the effect of pre-procedural antimicrobial exposure on BAL yield remains uncertain. Our study aimed to evaluate associations between pre-bronchoscopy antimicrobial exposure and BAL microbiological yield. Methods: We analysed data from a prospective registry of immunocompromised patients undergoing bronchoscopy with BAL at a tertiary hospital between May 2021 and May 2024. Positive BAL yield was defined as positive bacterial or fungal culture, viral polymerase chain reaction (PCR), or BAL galactomannan (GM) >0.5. Associations between antimicrobial exposure and BAL yield were analysed. Results: A total of 113 bronchoscopies were performed in 107 ICH. Prior to bronchoscopy, 85% had received antibiotics, 41.6% antivirals, and 26.5% antifungals. BAL yielded at least one positive result in 76.1% of procedures, including bacterial cultures (23.0%), fungal cultures (67.3%), viral PCR (27.4%), and GM >0.5 (15.0%). Prophylactic antibiotics [odds ratio (OR) 0.168, 95% confidence interval (CI): 0.037-0.762, P=0.01] and empiric antibiotics ≥24 h (OR 0.262, 95% CI: 0.100-0.687, P=0.005) were associated with reduced bacterial culture yield. Prophylactic antifungal exposure reduced fungal culture yield (OR 0.206, 95% CI: 0.073-0.584, P=0.002). Conversely, antiviral exposure increased odds of positive viral PCR (OR 2.997, 95% CI: 1.274-7.051, P=0.01), while empiric antifungals ≥48 h increased odds of positive GM (OR 9.538, 95% CI: 1.915-47.505, P=0.01). Conclusions: Pre-bronchoscopy exposure to antibiotics and antifungals was associated with reduced bacterial and fungal yields respectively, supporting the value of early BAL. Viral PCR and GM assays remained informative despite antimicrobial exposure. The perceived reduction in yield should be weighed against the persistent diagnostic utility of BAL, especially for viral and fungal pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.